Bio-Path Hldgs
(NASDAQ:BPTH)
$5.84
2.60[80.25%]
At close: Apr 18
$5.84
0[0.00%]
PreMarket: 7:32AM EDT
Why is it moving?
Bio-Path Holdings shares are trading higher after the company announced the completion of its second dose cohort in Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest

Bio-Path Hldgs Stock (NASDAQ:BPTH), Quotes and News Summary

Bio-Path Hldgs Stock (NASDAQ: BPTH) stock price, news, charts, stock research, profile.

Open-
Close-
Volume / Avg.1.736M / 38.846K
Day Range- - -
52 Wk Range2.705 - 44.800
Market Cap$4.402M
P/E Ratio-
Dividend Yield-
ExchangeNASDAQ
RSI
61
Short Interest
8.96%
Days to Cover1.92

Recent News

Why Bio-Path Holdings Shares Are Falling Today
Bio-Path reported a net loss of $33.63 per share for the year ended Dec. 31, 2023, lower than $38.12 per share in the year-ago period.
Nabaparna Bhattacharya
Why UP Fintech Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Shares of UP Fintech Holding Limited (NASDAQ: TIGR) surged in pre-market trading after the company results for the third quarter.
Lisa Levin
Why Talaris Therapeutics Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Gainers Biocept, Inc. (NASDAQ: BIOC) shares surged 91.8% to $0.98 in pre-market trading after falling over 6% on Tuesday. Biocept recently filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware.
Lisa Levin
-%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trend
1
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
About Bio-Path Holdings Inc
Sector
Health Care
Industry
Biotechnology
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug de...
Show More

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
BPTH
DRMA

FAQ

Q

How do I buy Bio-Path Hldgs (BPTH) stock?

A

You can purchase shares of Bio-Path Hldgs (NASDAQ: BPTH) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Bio-Path Hldgs's (BPTH) competitors?

A

Other companies in Bio-Path Hldgs’s space includes: Dermata Therapeutics (NASDAQ:DRMA), NeuBase Therapeutics (NASDAQ:NBSE), Bone Biologics (NASDAQ:BBLG), Quoin Pharmaceuticals (NASDAQ:QNRX) and Qualigen Therapeutics (NASDAQ:QLGN).

Q

What is the target price for Bio-Path Hldgs (BPTH) stock?

A

The latest price target for Bio-Path Hldgs (NASDAQ: BPTH) was reported by Roth MKM on Wednesday, March 27, 2024. The analyst firm set a price target for 40.00 expecting BPTH to rise to within 12 months (a possible 584.93% upside). 1 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Bio-Path Hldgs (BPTH)?

A

The stock price for Bio-Path Hldgs (NASDAQ: BPTH) is $5.84 last updated Today at April 18, 2024 at 7:32 AM EDT.

Q

Does Bio-Path Hldgs (BPTH) pay a dividend?

A

There are no upcoming dividends for Bio-Path Hldgs.

Q

When is Bio-Path Hldgs (NASDAQ:BPTH) reporting earnings?

A

Bio-Path Hldgs’s Q1 earnings are confirmed for Friday, May 10, 2024.

Q

Is Bio-Path Hldgs (BPTH) going to split?

A

There is no upcoming split for Bio-Path Hldgs.

Q

What sector and industry does Bio-Path Hldgs (BPTH) operate in?

A

Bio-Path Hldgs is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch